Skip to Content

Generic Inbrija Availability

Last updated on Sep 8, 2021.

Inbrija is a brand name of levodopa, approved by the FDA in the following formulation(s):

INBRIJA (levodopa - powder;inhalation)

  • Manufacturer: ACORDA
    Approval date: December 21, 2018
    Strength(s): 42MG [RLD]

Has a generic version of Inbrija been approved?

No. There is currently no therapeutically equivalent version of Inbrija available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inbrija. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • High efficient delivery of a large therapeutic mass aerosol
    Patent 6,858,199
    Issued: February 22, 2005
    Inventor(s): Edwards; David A. & Batycky; Richard P. & Johnston; Lloyd
    Assignee(s): Advanced Inhalation Research, Inc.

    A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g/cm3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm3.

    Patent expiration dates:

    • November 4, 2021
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
  • Inhalation device and method
    Patent 7,146,978
    Issued: December 12, 2006
    Inventor(s): Edwards; David & DeLong; Mark & Dunbar; Craig & Penachio; Ernest E. & Stapleton; Kevin & Wolff; Mark
    Assignee(s): Advanced Inhalation Research, Inc.

    Inhalation device and associated method for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device has a chamber for receiving the receptacle. A ring is circumferentially coupled to an inner surface of the chamber to achieve a higher reproducible emitted dose of medicament from the receptacle. The inhalation device also includes an improved implement for puncturing the receptacle, requiring less force and experiencing fewer failures.

    Patent expiration dates:

    • April 16, 2021
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
  • Particulate compositions for pulmonary delivery
    Patent 7,182,961
    Issued: February 27, 2007
    Inventor(s): Batycky; Richard P. & Edwards; David A. & Lipp; Michael M.
    Assignee(s): Advanced Inhalation Research, Inc.

    This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (σ) is greater than 2, optimally greater than 3.

    Patent expiration dates:

    • February 22, 2024
      ✓ 
      Drug product
  • Particulate compositions for pulmonary delivery
    Patent 7,384,649
    Issued: June 10, 2008
    Inventor(s): Batycky; Richard P. & Edwards; David A. & Lipp; Michael M.
    Assignee(s): Advanced Inhalation Research, Inc.

    This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (σ) is greater than 2, optimally greater than 3.

    Patent expiration dates:

    • November 20, 2022
      ✓ 
      Drug product
  • Highly efficient delivery of a large therapeutic mass aerosol
    Patent 7,556,798
    Issued: July 7, 2009
    Inventor(s): Edwards; David A. & Batycky; Richard P. & Johnston; Lloyd
    Assignee(s): Alkermes, Inc.

    A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.

    Patent expiration dates:

    • November 4, 2021
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
  • Pulmonary delivery for levodopa
    Patent 8,404,276
    Issued: March 26, 2013
    Assignee(s): Civitas Therapeutics, Inc.

    In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

    Patent expiration dates:

    • March 19, 2023
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
  • Capsules containing high doses of levodopa for pulmonary use
    Patent 8,545,878
    Issued: October 1, 2013
    Assignee(s): Civitas Therapeutics, Inc.

    The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

    Patent expiration dates:

    • November 16, 2032
      ✓ 
      Drug product
  • Pulmonary delivery for levodopa
    Patent 8,586,093
    Issued: November 19, 2013
    Assignee(s): Civitas Therapeutics

    In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

    Patent expiration dates:

    • March 19, 2023
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
  • Capsules containing high doses of levodopa for pulmonary use
    Patent 8,685,442
    Issued: April 1, 2014
    Assignee(s): Civitas Therapeutics, Inc.

    The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

    Patent expiration dates:

    • November 16, 2032
      ✓ 
      Drug product
  • Capsules containing high doses of levodopa for pulmonary use
    Patent 8,945,612
    Issued: February 3, 2015
    Assignee(s): Civitas Therapeutics, Inc.

    The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

    Patent expiration dates:

    • November 16, 2032
      ✓ 
      Drug product
  • Pulmonary delivery for levodopa
    Patent 9,155,699
    Issued: October 13, 2015
    Assignee(s): Civitas Therapeutics, Inc.

    In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

    Patent expiration dates:

    • March 19, 2023
      ✓ 
      Drug product
  • Capsules containing high doses of levodopa for pulmonary use
    Patent 9,393,210
    Issued: July 19, 2016
    Assignee(s): Civitas Therapeutics, Inc.

    The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

    Patent expiration dates:

    • November 16, 2032
      ✓ 
      Drug product
  • Pulmonary delivery for levodopa
    Patent RE43711
    Issued: October 2, 2012
    Inventor(s): Jackson; Blair & Bennett; David J. & Bartus; Raymond T. & Emerich; Dwaine F.
    Assignee(s): Civitas Therapeutics, Inc.

    In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

    Patent expiration dates:

    • February 3, 2029
      ✓ 
      Patent use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 21, 2021 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.